How Can We Help?
You are here:
< Back

Ebalzotan (NAE-086) is a selective 5-HT1A receptor agonist.[1][2] It was under development as an antidepressant and anxiolytic agent but produced undesirable side effects in phase I clinical trials and was subsequently discontinued.[1][2]

See also

References

  1. ^ a b Braish T, Gadamasetti KG (2008). Process chemistry in the pharmaceutical industry, volume 2 challenges in an ever changing climate. Boca Raton: CRC Press. ISBN 978-0-8493-9051-7.
  2. ^ a b Weaver DF, Nogrady T, Nogrady T (2005). Medicinal chemistry a molecular and biochemical approach. Oxford [Oxfordshire]: Oxford University Press. ISBN 0-19-510455-2.
Categories
Table of Contents